Overview: F8 Gene Mutation TestIntroduction: The F8 Gene Mutation Test tests for F8 gene mutations to diagnose hemophilia A, causing excessive bleeding or bruising, aiding in genetic diagnosis and treatment planning. Affecting 1 in 5,000 males, hemophilia A poses diagnostic challenges due to its X-linked inheritance. Following 2023 World Federation of Hemophilia (WFH) guidelines, it uses PCR/sequencing for high accuracy, supporting molecular pathology screening. This test is vital for diagnosis, therapy management, and improving outcomes in hematology.
Other Names: Hemophilia A Gene Test, F8 Mutation Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: Genetic testing for hemophilia began in the 1980s with research by Lawn, who mapped the F8 gene. PCR/sequencing advancements in the 2000s by Illumina improved detection, surpassing earlier linkage analysis methods.
Purpose: Detects F8 mutations to diagnose hemophilia A, guides factor replacement therapy, and evaluates patients with bleeding, aiming to prevent complications.
Test Parameters: F8 gene mutations
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of bleeding issues.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document excessive bleeding or bruising. Include current medications or family history of bleeding disorders.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., hemorrhage), and sample collection risks.
Procedural Considerations: Uses PCR/sequencing to detect mutations, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive mutations confirm hemophilia A, guiding therapy. Early treatment might prevent bleeding, while untreated cases lead to joint damage. Normal results may require clotting tests.
Specialist Consultation: Consult a hematologist or genetic counselor for interpretation.
Additional Supporting Tests: APTT, factor VIII level, or genetic panel to confirm diagnosis.
Test Limitations: Specific to F8 gene; correlation with symptoms needed. False negatives possible with untested variants.
References: WFH Guidelines, 2023; Blood, Lawn RM, 2022.
